Earnings Releases·Nov 5, 2026, 7:04 AM ET

Korro Bio — Third Quarter 2026 Earnings Summary

Reported a net loss of $17.5 million for Q3 2026, a decrease from $18.1 million in the prior year period, while collaboration revenue fell to $0 from $1.1 million due to a 12-month pause in the Novo Nordisk agreement.
Cash, cash equivalents, and marketable securities increased to $124.8 million as of September 30, 2026, from $85.2 million at year-end 2025, providing a runway to support operations and capital expenditures into the second half of 2028.
Initiated dosing of healthy volunteers in the Phase 1/2 ANCHOR trial for KRRO-121 in September 2026 and received FDA Rare Pediatric Disease designation for UCDs; KRRO-111 demonstrated >95% SERPINA1 transcript editing in preclinical models.
Guidance includes dosing UCD participants in the ANCHOR trial during the first half of 2027, reporting interim data in the second half of 2027, and submitting a regulatory application for KRRO-111 in the first half of 2027.